Poster Abstracts • OFID 2017:4 (Suppl 1) • S467 penicillin G (PEN; from 30.3% in 2009 to 16.0% in 2015 and ceftriaxone (CRO; from 27.3% to 12.0%), as did PCV13 STs (from 34.5% to 16.0%% and from 27.5% to 8.6%, respectively). ST 19F showed stable S patterns over time and 19A remained the less S ST with high NS rates for PEN (49.0%-76.5%), .8%), erythromycin (ERY; 76.9-90.8%), and clindamycin (CLI; 51.0-73.1%). These NS rates for 19A rose from 2009 to 2011-2012, decreasing in 2013-2016 Methods. IPD cases are reported to a central office and one isolate/case is serotyped. Demographic/ clinical data are collected by chart review and patient/physician interview.
Changing Epidemiology of Invasive Pneumococcal
Since 1/1/2015, there has been no IPD due to PCV7 STs in children. In adults, 57 episodes include 19 of ST4, 13 ST19F, 8 ST14, 7 ST6B, 5 ST9V, 3ST18C and 2 ST23F. The median age of patients was 64.5y (range 28-98), 37 were male; 67% had an underlying illness. PCV7 ST cases were more likely to be associated with group housing than other cases (12/45, 21%, v 47/644, 7%, P < .01); 6/19 cases of ST4 were associated with a single homeless shelter, and 3/8 due to ST14 occurred in one nursing home.
Of 188 episodes due to PCV13/not PCV7 serotypes, 87 were due to ST3, 72 ST19A, 16 ST7F, 11 ST6A, and 1 each due to ST1 and ST5. 22 cases occurred in children (12 ST3, 9 ST19A, 1 ST7F): 1 child refused consent, and 1 had missing data; 4 were vaccine ineligible; 2 unvaccinated; 9 incompletely vaccinated; and 5 vaccine failures (2 ST3, 3 ST19A). The most recent case of pediatric IPD due to ST19A was in Aug/2016; both pediatric cases to date in 2017 are ST3. The incidence of IPD due to STs 19A and 3 over time in children and adults is shown in the Figures.
Conclusion. Since PCV13-program implementation, IPD due to PCV7 STs has decreased to zero among children and remains low in adults, although clusters in communal living situations may be emerging. IPD due to ST19A has declined dramatically. IPD incidence due to ST3 has not changed significantly since 1995.
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No reported disclosures. Background. Although a substantial decline in overall vaccine serotype invasive pneumococcal disease (IPD) incidence has been observed following immunization with PCV7 and subsequently PCV13, the reported effectiveness for individual vaccine serotypes has varied. Reported effectiveness of PCV13 for serotype 3 (ST3) disease has differed by study design and geography, with a wide range of estimates including zero. We assessed the impact of PCV13 on ST3 IPD cases and nasopharyngeal (NP) carriage in Massachusetts' children.
Impact of PCV13 on
Methods. Cases of ST3 IPD in children <18 years were identified via enhanced passive surveillance in conjunction with the Massachusetts Department of Public Health from 2002 to 2016. NP Carriage of ST3 in children aged 3 months to <7 years was identified via an active surveillance network of pediatric practices in Massachusetts from 2007 to 2014. Annual incidence rates of ST3 IPD were calculated using US Census estimates as population denominators. Annual prevalence rates of carriage were calculated using the surveillance population. We compared age distribution, clinical syndromes, presence of comorbidities and vaccination status for IPD cases and age distribution of children with ST3 carriage before and after PCV13 implementation.
Results. Overall 47 cases of ST3 IPD were identified from 2002 to 2016; the incidence of ST3 IPD before and after PCV13 was 0.23 and 0.20 per 100,000 children respectively (incidence rate ratio [IRR] = 1.13, 95% CI 0.62-2.05). There were no differences in age distribution, clinical syndrome or presence of comorbidities among ST3 IPD cases before and after PCV13. The majority (9/13) of post PCV13 ST3 IPD cases occurred among children who were fully vaccinated. No association was seen between date of last PCV13 dose and time of IPD to suggest waning immunity. Prevalence of ST3 carriage among children aged 3 months to <7 years before and after PCV13 implementation was 0.19 and 0.64 respectively (Prevalence ratio [PR] = 0.3, 95% CI 0.11-0.83).
Conclusion. Six years after PCV13 implementation, no significant changes in ST3 IPD incidence, age distribution, clinical syndrome or presence of comorbidity among cases in children <18 years of age were observed. An increase in NP carriage in children <7 years of age was observed. 
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